JAMA confirms DTC drove 'Low-T' craze

A recent report shows the strength of DTC advertising and how it can be abused. 

By Lisa LaMotta • March 23, 2017

J&J, GSK pull ads from YouTube amid display concerns

A growing list of major corporations have paused advertising on the media channel due to alarm that product marketing may be appearing next to offensive material. 

By Ned Pagliarulo • March 23, 2017

Explore the Trendline➔

Commercialization

New drugs for obesity and Alzheimer’s look set to become blockbusters, reshaping pharma marketing strategies just as many current top-sellers near looming patent cliffs.

By BioPharma Dive staff

Newron finally secures US approval for Parkinson's drug

Xadago has been approved in the EU since early 2015, but troubles with the FDA had kept it off the U.S. market until now. 

By Suzanne Elvidge • March 22, 2017

Lilly offers up drug pricing details amid ongoing scrutiny of industry

Following criticism over the cost of its insulin drugs, the company gave a glimpse into its pricing decisions in an annual report.

By Jacob Bell • March 20, 2017

FDA advisory panel votes against Endo's opioid painkiller

After the panel concluded the risks associated with Opana ER outweigh its benefits, the FDA will now have to decide what reforms to take for the prescription opioid.

By Jacob Bell • March 15, 2017

OncBioMune, EOC aim to develop gastric cancer drug

The commercialization deal is part of the Louisiana-based biopharma’s push southward into Mexico, Central America and South America.

By Judy Packer-Tursman • March 15, 2017

Bernie Sanders calls for more broadcast news on drug pricing

The Vermont senator sent a letter to Fox News, CNN and four other television news networks criticizing their lack of coverage on pharmaceutical pricing.

By Jacob Bell • March 15, 2017

Acorda taps Amazon's Alexa to build MS awareness

Say "Alexa, start MS Awareness," and Amazon's voice recognition software will deliver facts and tips about multiple sclerosis from Acorda's app. 

By Suzanne Elvidge • March 15, 2017

Mylan clears way for biosimilar Herceptin launch in US

The EpiPen manufacturer reached a settlement deal with Roche, granting Mylan a license to commercialize what could be the first Herceptin copy in the U.S. 

By Ned Pagliarulo • March 13, 2017

Using social to tap into the rare disease market

The annual Rare Disease Day is designed to connect the rare disease community, build awareness and raise research funds.

By Judy Packer-Tursman • March 10, 2017

5 biotech CEOs on payers, investors and big bets

BioPharma Dive sat down with the top executives from several biotechs at the BIO CEO conference in New York. Here is what they had to say about the challenges they face, dealing with payers and educating investors. 

By Lisa LaMotta • March 9, 2017

Express Scripts challenges Gilead in pricing blame game

The pharmacy benefit manager fired back at Gilead, calling on the drugmaker to lower the costs of its hepatitis C medicines and reimburse payers. 

By Lisa LaMotta • March 8, 2017

MS drugs too expensive, ICER says

A new report from the Institute for Clinical and Economic Review found only Sanofi's Lemtrada met its cost-effectiveness benchmark. 

By Ned Pagliarulo • March 7, 2017

Amgen debuts Repatha ad amid ongoing patent battle

The 1-minute clip touts the PCSK9 drug's potential as a better cholesterol-lowering option than statin monotherapy.

By Jacob Bell • March 7, 2017

Pressure builds on Marathon over orphan drug price

A group of senators sent a letter asking for answers from the drugmaker on how it decided to price its newly approved DMD treatment at $89,000 per year. 

By Ned Pagliarulo • March 7, 2017

FDA gives go-ahead to Lexicon's rare disease drug

The company plans to price Xermelo, a drug for carcinoid syndrome diarrhea, similarly to Novartis' leading treatment for the condition.

By Jacob Bell • March 1, 2017

Napo amps up sales force for AIDS anti-diarrheal

The San Francisco-based company, which has inked a deal for a shared sales and sampling program, expects Mytesi to generate about $7 million in sales this year.

By Judy Packer-Tursman • March 1, 2017

How DTC got things moving for Linzess

The biotech has transitioned through three iterations of its DTC campaign for Linzess in as many years, despite each one being successful. 

By Lisa LaMotta • March 1, 2017

Allergan eyes up dry eye patients

"Before we had our voice, we had our eyes," reminds the Eyepowerment campaign created to empower patients to look more closely at their dry eyes. 

By Suzanne Elvidge • March 1, 2017

Beleaguered Valeant ups Salix sales force

A day before releasing fourth-quarter 2016 earnings, the struggling Canadian specialty phama said it has scaled up its sales force by nearly 40% for two of its best-selling GI drugs.

By Judy Packer-Tursman • Feb. 28, 2017

Industry Pulse: Who's spending on R&D?

As top-selling drugs age, biopharma continues to hunt for ever-elusive innovation. Here are eight charts explaining which pharmas need it most, and which are turning to internal R&D to capture it. 

By Ned Pagliarulo • Feb. 28, 2017

J&J unpacks pricing decisions in new transparency report

The mega-pharma's subsidiary Janssen debuted a report aiming to break down the complexities related to drug pricing.

By Jacob Bell • Feb. 27, 2017

Why drug pricing seems so complicated

Experts say pharma companies need to get better at incorporating clinical value into pricing and communicating this value.

By Judy Packer-Tursman • Feb. 27, 2017

Pfizer, Celltrion pushing for interchangeability with Inflectra

Positive data could support a claim of interchangeability for the biosimilar of Remicade. 

By Jacob Bell • Feb. 22, 2017

PhRMA launches Go Boldly's first science dialogue

The industry trade group has launched a new marketing and outreach effort aimed at turning attention away from drug prices and toward progress in pharmaceutical science.

By Judy Packer-Tursman • Feb. 22, 2017